€8.50
15.59% yesterday
Xetra, Nov 22, 05:43 pm CET
ISIN
DE0005664809
Symbol
EVT
Index
Sector
Industry

Evotec Stock price

€8.50
+2.56 43.10% 1M
-1.11 11.50% 6M
-12.78 60.06% YTD
-10.67 55.65% 1Y
-34.27 80.13% 3Y
-10.35 54.91% 5Y
+5.23 160.02% 10Y
Xetra, Closing price Fri, Nov 22 2024
-1.57 15.59%
ISIN
DE0005664809
Symbol
EVT
Index
Sector
Industry

Key metrics

Market capitalization €1.51b
Enterprise Value €1.67b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.15
P/S ratio (TTM) P/S ratio 1.94
P/B ratio (TTM) P/B ratio 1.56
Revenue (TTM) Revenue €777.05m
EBIT (operating result TTM) EBIT €-135.27m
Free Cash Flow (TTM) Free Cash Flow €-204.59m
Cash position €303.27m
EPS (TTM) EPS €-0.97
P/E forward negative
P/S forward 1.86
EV/Sales forward 2.06
Show more

Is Evotec a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Evotec Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Evotec forecast:

8x Buy
67%
3x Hold
25%
1x Sell
8%

Analyst Opinions

12 Analysts have issued a Evotec forecast:

Buy
67%
Hold
25%
Sell
8%

Financial data from Evotec

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
777 777
3% 3%
100%
- Direct Costs 671 671
16% 16%
86%
106 106
39% 39%
14%
- Selling and Administrative Expenses 180 180
118% 118%
23%
- Research and Development Expense 61 61
20% 20%
8%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -135 -135
130% 130%
-17%
Net Profit -171 -171
2% 2%
-22%

In millions EUR.

Don't miss a Thing! We will send you all news about Evotec directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Evotec Stock News

EQS
about 12 hours ago
Der Vorstand und Aufsichtsrat von Evotec befanden sich zusammen mit ihren Beratern in der Prüfung des unverbindlichen Angebots der Halozyme Therapeutics Inc., die in einem Schreiben vom 13. November 2024 ihr Interesse an einem Zusammenschluss von Halozyme mit Evotec bekundet hatte.
AD HOC NEWS
one day ago
Evotec SE / DE0005664809
AD HOC NEWS
one day ago
Die Aktien von Evotec DE0005664809 sind am Freitagnachmittag nach einem zurückgezogenen Übernahmeangebot des US-Wirkstoffforschers Halozyme US40637H1095 eingebrochen.
More Evotec News

Company Profile

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmes on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Head office Germany
CEO Christian Wojczewski
Employees 5,000
Founded 1993
Website evotec.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today